Oncternal Therapeutics Stock EBITDA
| ONCTDelisted Stock | USD 0.53 0.00 0.00% |
Oncternal Therapeutics fundamentals help investors to digest information that contributes to Oncternal Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncternal Stock. The fundamental analysis module provides a way to measure Oncternal Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncternal Therapeutics stock.
Oncternal |
Oncternal Therapeutics Company EBITDA Analysis
Oncternal Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Oncternal Therapeutics EBITDA | 2.23 M |
Most of Oncternal Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncternal Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Oncternal Therapeutics reported earnings before interest,tax, depreciation and amortization of 2.23 M. This is 99.75% lower than that of the Biotechnology sector and 97.77% lower than that of the Health Care industry. The ebitda for all United States stocks is 99.94% higher than that of the company.
Oncternal EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncternal Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncternal Therapeutics could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics of similar companies.Oncternal Therapeutics is currently under evaluation in ebitda category among its peers.
Oncternal Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.83 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 12.07 % | ||||
| Number Of Shares Shorted | 14.21 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.17 X | ||||
| Price To Sales | 0.72 X | ||||
| Revenue | 785 K | ||||
| Gross Profit | (31.49 M) | ||||
| EBITDA | 2.23 M | ||||
| Net Income | (39.48 M) | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.78 X | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (11.69) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 1.56 M | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Working Capital | 30.86 M | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
| Net Asset | 36.73 M |
About Oncternal Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncternal Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncternal Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncternal Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |